Clinical Commentary · The Fascia Institute
GLP-1, Mast Cell Activation, and the Hypermobile Body.
A clinical commentary on a class of medication that is changing the conversation in lipedema, hypermobile EDS, and mast cell activation — and on what a responsible program around it has to look like.
By Jacques Courseault, MD, FAAPMR — Founder & Medical Director, The Fascia Institute and Treatment Center®.
For the last two years, I have watched a quiet reshuffling of medicine play out in my own clinic. Patients I have followed for hypermobile Ehlers-Danlos syndrome (hEDS), lipedema, mast cell activation syndrome (MCAS), POTS, and the long tail of overlapping connective-tissue conditions began arriving with a question that nobody trained us to answer cleanly.
“Should I be on a GLP-1?”
I want to give you the clearest, most honest answer I can — because the medical literature is finally starting to catch up to what these patients have been telling us, and because the answer is more interesting than either the marketing or the backlash suggests.
The short version: GLP-1 receptor agonists are not just weight-loss drugs. There is now real, mechanistic, peer-reviewed evidence that they modulate mast cells, calm systemic inflammation, and, in selected patients with connective tissue and immunologic overlap, may do something we have never had a tool to do before. But in the hypermobile body — already vulnerable to gastroparesis, autonomic instability, fascial pain, and dysregulated tissue remodeling — these drugs can also do real harm if they are prescribed casually. They are not a med-spa medication for this population. They demand a physician-run, monitored program built specifically for the connective tissue patient.
That is why we built one. This article is the clinical case for it.
The Discovery That Changed the Conversation.
In July 2025, a case series was published in The American Journal of the Medical Sciences that, in my view, will be looked back on as a turning point. The investigators followed 47 patients (mean age 39, 89% female) with diagnosed mast cell activation syndrome who were placed on GLP-1 receptor agonists — primarily semaglutide and tirzepatide. Eighty-nine percent demonstrated meaningful clinical benefit. Improvements were not limited to weight or glycemic control. Patients reported reductions in flushing, GI reactivity, neurologic symptoms, and autonomic dysregulation, often within hours to days of dose escalation — far faster than fat loss alone could explain.
The mechanism is not mysterious. Mast cells express functional GLP-1 receptors. When those receptors are engaged, the threshold for mast cell degranulation rises. Histamine, tryptase, prostaglandin D2, and the broader inflammatory cascade we treat reactively in MCAS clinics every week appear to be released less aggressively. In parallel, GLP-1 receptor agonists exert systemic anti-inflammatory effects through reductions in TNF-α, IL-6, and CRP that have now been documented across multiple trials in cardiometabolic populations.
For a clinician who has spent a decade treating MCAS–EDS overlap with antihistamines, mast cell stabilizers, low-histamine diets, and biologics that work imperfectly, this is not a marketing slogan. It is a new lever. We should treat it as one.
Why Lipedema, Hypermobility, and Mast Cell Disease Cluster.
Before we discuss treatment, it is worth saying out loud what experienced clinicians in this space already know but the broader medical community still resists: lipedema, hypermobility spectrum disorders, hEDS, and MCAS are not coincidences in the same patient. They are expressions of overlapping connective-tissue and immune biology.
A 2025 cross-sectional study documenting the shared pathophysiology between lipedema and hypermobility spectrum disorders mirrors what I see clinically every week. Both involve dysregulated extracellular matrix. Both involve abnormal fascia. Both involve a chronic, low-grade inflammatory tone that does not look like classical obesity. The lipedema literature from 2024 and 2025 has moved decisively toward describing the disease as an inflammatory adipose disorder — one in which adipose tissue is infiltrated by macrophages (predominantly M2-polarized), fibroblasts, and mast cells, with crown-like structures around necrotizing adipocytes and active fibrotic remodeling. The 2025 hormonal model implicates ERβ/ERα imbalance and local estrogen excess as accelerators, particularly around menopause.
Translation: lipedema is not a body composition problem. It is a connective tissue and immune problem that happens to present as fat that does not respond to caloric restriction. And the patient who carries it disproportionately also carries hypermobility, MCAS, dysautonomia, and the constellation of symptoms our field has historically labeled “functional” because we did not have a unifying biology.
We do now.
The Therapeutic Logic in This Population.
If you accept the biology above, the therapeutic logic of a GLP-1 receptor agonist in a hypermobile, lipedematous, mast-cell-driven patient is not “lose weight.” It is layered:
- Mast cell stabilization — direct receptor-mediated reduction in degranulation threshold.
- Reduction of systemic inflammatory tone — measurable in CRP, IL-6, TNF-α; clinically detectable in flare frequency.
- Reduction of adipose-driven inflammation — particularly relevant to lipedema, where the adipose tissue itself is the immunologic offender.
- Mechanical offloading of unstable joints — fat-mass reduction (when controlled and lean-mass-preserving) reduces axial and peripheral joint loading in patients whose ligamentous restraint is already compromised.
- Improvement in metabolic and cardiovascular comorbidities that disproportionately afflict this population, including insulin resistance and lipid dysregulation that often coexist with lipedema despite normal-appearing diets.
Done correctly, this is a connective-tissue intervention dressed up as a metabolic one. Done incorrectly, it can accelerate the very problems it was meant to address.
The Risks the Mainstream Conversation Underestimates.
I want to be very direct about what I see in the EDS and lipedema community when GLP-1 medications are prescribed without an understanding of the underlying biology.
Gastroparesis is already endemic in this population. Up to half of hEDS patients report delayed gastric emptying, severe constipation, or nausea at baseline. GLP-1 receptor agonists slow gastric emptying as a primary pharmacologic action. Layering pharmacologic dysmotility on top of connective-tissue dysmotility is not a small clinical decision. Aggressive titration in this group can produce intractable nausea, vomiting, food avoidance, electrolyte derangement, and, in the worst cases, hospitalization. We have published case reports of this. It is not theoretical.
Lean mass loss is disproportionate in hypermobile patients. Real-world data suggest that up to 40% of total weight lost on GLP-1 therapy can come from lean body mass, including skeletal muscle. In a patient whose joints are stabilized primarily by muscle because their ligaments cannot do the job, every kilogram of lost muscle is a measurable loss of joint protection. Subluxation rates can rise. Functional capacity can fall. Patients can finish a course of GLP-1 therapy thinner, weaker, and more symptomatic than when they started.
Fascial pain and “Ozempic face” are tissue-remodeling problems. When subcutaneous fat is lost rapidly, the overlying fascia and skin must remodel to accommodate the new volume. In normal connective tissue, this happens slowly but adequately. In hEDS and lipedema, where the extracellular matrix is already abnormal and the remodeling machinery is already dysregulated, the result can be visible facial deflation, but also a less-discussed and very real syndrome of diffuse fascial pain, pulling sensations, and worsening myofascial trigger points as superficial and deep fascia adapt unevenly to a rapidly changing volume. I see this in my office. It is one of the most underreported side effects of rapid GLP-1 weight loss in connective-tissue patients.
Autonomic destabilization is a real risk in POTS. GLP-1 medications affect gastric emptying, fluid distribution, and cardiovascular reflexes. In an already-dysautonomic patient, dose escalation can transiently worsen pre-syncope, palpitations, and exercise intolerance.
Mental health and disordered eating histories warrant explicit screening. This population is at higher baseline risk for restrictive eating patterns, and these medications suppress appetite profoundly.
None of this is an argument against the drugs. It is an argument against prescribing them like a med-spa membership.
What a Connective-Tissue–Aware GLP-1 Program Has to Look Like.
When we sat down to design the FIT Lipedema and Inflammation Program (FLIP) at The Fascia Institute and Treatment Center®, we started from a single premise: if this medication class is going to be safe and effective in the hypermobile patient, the program around the prescription matters more than the prescription itself. A monthly auto-shipment of pens with no clinical scaffolding is precisely the wrong delivery model for this population.
FLIP is built around five non-negotiables.
Physician-run titration, not algorithmic titration.
Every patient starts and advances under the direct supervision of a physician trained in connective tissue disease, mast cell disorders, and the autonomic comorbidities that overlap with lipedema and hypermobility. Dose escalation in this population is slower than the manufacturer’s label. We explicitly under-titrate to find the lowest effective dose, not the highest tolerated one.
Three dose tiers with transparent monthly pricing.
Patients are placed in one of three dose tiers based on clinical need, tolerability, and metabolic response — not marketing pressure. The pricing is disclosed up front in the consent and financial agreement at intake. No surprise costs. No volume-based push to a higher tier.
Monthly physician check-ins with structured lab monitoring.
We monitor metabolic markers (lipids, fasting insulin, HbA1c, hsCRP), thyroid function, electrolytes, renal function, B12 and iron stores, and — where clinically indicated — tryptase and inflammatory markers. We are looking for the early signal of GI dysfunction, lean mass loss, micronutrient deficiency, or autonomic destabilization before the patient is symptomatic enough to call us. Monthly contact is a safety mechanism, not a billing event.
A clinical-grade body composition scale, sent home with every patient.
We do not measure progress on the bathroom scale. Each patient in FLIP is provided a clinical-grade body composition scale to keep at home, so we can track fat mass, lean mass, visceral fat, and segmental composition between visits — not just the day they sit in the office. Lean mass is a primary safety endpoint, not a secondary one. If a patient loses lean mass faster than fat mass, the protocol changes — protein intake is restructured, training load is restructured, dose may be held.
OxeFit resistance training membership through our partnership with FIT Therapeutics.
Through a clinical partnership between The Fascia Institute and Treatment Center® and FIT Therapeutics, every FLIP patient receives an OxeFit membership at the FIT Therapeutics training facility. OxeFit is a computer-controlled, smart strength-training platform that uses precision motorized cable resistance instead of conventional weights. Resistance is delivered electronically — load can be set in pound-by-pound increments, and the system can apply different resistance on the concentric and eccentric phases of a movement, change resistance mid-rep, and record exact force, velocity, and power for every set. The platform is in active use by professional athletes for performance training and by clinicians for rehabilitation. We selected it for FLIP for one specific reason: in the hypermobile patient, conventional free-weight training carries real joint risk at end range, and conventional bodyweight training under-loads the muscle. OxeFit’s controllable cable system lets us load the hypermobile patient precisely, without putting unstable joints into the positions that injure them — and the data it captures lets us prove, visit over visit, that the patient is preserving and building lean mass during GLP-1 therapy.
Wrapped around all of this is the broader clinical infrastructure of The Fascia Institute and Treatment Center® that these patients already need — Fascial Mapping® to document baseline tissue organization and follow it through weight change, Hydrofascia Release™ for the myofascial restrictions that emerge as tissue remodels, IV hydration support for the dysautonomic patient navigating the appetite and fluid shifts of early titration, and physician-led management of the MCAS, POTS, and EDS comorbidities — including our Hypermobility & EDS Clinic — that shape every dosing decision.
Who This Program Is For — and Who It Is Not For.
FLIP is appropriate for the patient with:
- Lipedema (any stage), particularly when accompanied by hypermobility, MCAS, or autonomic features
- Hypermobile EDS or hypermobility spectrum disorder with metabolic, inflammatory, or weight-related symptoms that have not responded to standard care — the population we already serve through our Hypermobility & EDS Clinic
- MCAS with significant systemic inflammation, particularly when overlapping with insulin resistance or refractory weight gain
- Connective-tissue patients who have tried — and tolerated poorly, or failed — unsupervised GLP-1 prescriptions and need a clinically rigorous reset
It is not appropriate for the patient who wants a fast-titration cosmetic weight-loss prescription with minimal clinical follow-up. There are clinics that do that. We are not one of them, and we will not become one.
The Bigger Picture.
The reason this matters beyond any one clinic is that we are at a hinge moment in how we treat connective tissue and mast cell disease. For thirty years, this population has been told that their symptoms are functional, somatic, anxious, or simply “deconditioning.” The hypermobile patient has been disbelieved by orthopedics, the MCAS patient has been disbelieved by allergy and immunology, and the lipedema patient has been disbelieved by every weight-loss program she has ever walked into. Now a class of drug originally developed for type 2 diabetes is producing measurable, reproducible improvements across all three groups — and the mechanistic explanation, mast cell receptor biology, finally connects diseases that have always belonged together.
This is good news. It is also a clinical responsibility. A drug class powerful enough to change the trajectory of these diseases is, by definition, powerful enough to do real harm if used carelessly in the wrong body. The hypermobile body is the wrong body for casual prescribing.
If you are a patient with lipedema, hEDS, MCAS, or the overlap, and you have been wondering whether GLP-1 therapy might help you — the answer is: possibly, and the conversation is worth having, but not with a clinician who is going to titrate you on a phone app and ship pens to your door. Have it with someone who understands that the fascia, the mast cell, the autonomic nervous system, and the adipose tissue in your body are part of the same conversation.
That is the conversation we built the FIT Lipedema and Inflammation Program to have.
Inquire about evaluation for FLIP.
If you are managing lipedema, hEDS, MCAS, or the overlap and want to discuss whether the FIT Lipedema and Inflammation Program is right for you, our team is happy to walk you through the intake process.
About the author.
Jacques Courseault, MD, FAAPMR is Founder and Medical Director of The Fascia Institute and Treatment Center® and FIT Therapeutics. Board-certified in Physical Medicine & Rehabilitation, his clinical and research focus is the fascial system, hypermobility spectrum disorders, mast cell activation, and the integrated care of patients with overlapping connective tissue and inflammatory disease.
Selected References.
- Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome — American Journal of the Medical Sciences, 2025. PMID 40675372.
- Lipedema and Hypermobility Spectrum Disorders Sharing Pathophysiology: A Cross-Sectional Observational Study — PMC12565064, 2025.
- Lipedema and adipose tissue: current understanding, controversies, and future directions — Frontiers in Cell and Developmental Biology, 2025.
- Lipedema: A Disease Triggered by M2 Polarized Macrophages? — Biomedicines, 2025. PMC11940465.
- GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery — PMC11620716, 2024.
- Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient — PMC12497442, 2025.
- Lipedema World Alliance Delphi Consensus-Based Position Paper on the Definition and Management of Lipedema — 2023 Lipedema World Congress, Potsdam.
- Mast Cell Activation Syndrome: A Primer for the Practicing Clinician — PMID 34681933.
- The Hidden Risks of Ozempic and Wegovy in Ehlers-Danlos Syndrome Patients — The EDS Clinic, clinical commentary.